Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17168948 | 0.91 | KMO (0.47) | KMOCYP17A1CHRM4CD274L3MBTL1 | |
| SCHEMBL23875068 | 0.86 | HRH4 (0.42) | KMOCHRM4 | |
| SCHEMBL6267576 | 0.84 | CDC7 (0.37) | KMOCYP17A1 | |
| Aniline SCHEMBL27349687 | 0.84 | ADORA2A (0.38) | KMOCYP17A1RET | |
| SCHEMBL15898502 | 0.83 | KMO (0.38) | KMOCYP17A1 | |
| SCHEMBL16441792 | 0.83 | KMO (0.48) | KMOCYP17A1EGLN2RETL3MBTL1 | |
| SCHEMBL1661899 | 0.73 | KMO (0.46) | KMOCYP17A1EGLN2L3MBTL1 | |
| SCHEMBL6119719 | 0.73 | KMO (0.42) | KMOCYP17A1RET | |
| SCHEMBL15446373 | 0.73 | KMO (0.42) | KMOCYP17A1EGLN2L3MBTL1 | |
| SCHEMBL29878478 | 0.73 | KMO (0.46) | KMOCYP17A1EGLN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547336-A1 | USP1 INHIBITORS AND USES THEREOF | Zentaur Therapeutics USA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119836421-A | USP1 inhibitors and uses thereof | 森韬医药美国公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024006879-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-3418280-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-11358967-B2 | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-14 | — | — | US | disclosed |
| US-20210171527-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-06-10 | — | — | US | disclosed |
| EP-3405470-B1 | PYRAZINEDIHYDROPYRIMIDINONE OR PYRIDAZINEDIHYDROPYRIMIDINONE COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2020-07-15 | — | — | EP | disclosed |
| US-10450314-B2 | Pteridine derivatives as modulators of ROR gamma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| EP-3356366-B1 | PTERIDINE DERIVATIVES AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2019-08-28 | — | — | EP | disclosed |
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| CN-1024489-C | Method for controlling harmful insects and microorganisms on plants | CIBA GEIGY AG (CH) | 1994-05-18 | — | — | CN | disclosed |
| CN-1064270-A | Harmful insect and method of microorganism on the controlling plant | CIBA GEIGY AG (CH) | 1992-09-09 | — | — | CN | disclosed |
| CN-1064191-A | The composition of control or prevention harmful insect or microorganism encroach | CIBA GEIGY AG (CH) | 1992-09-09 | — | — | CN | disclosed |
| CN-1017993-B | Process for preparing anilinopyrimidine derivatives | CIBA GEIGY AG (CH) | 1992-08-26 | — | — | CN | disclosed |
| CN-1032441-A | Pesticide | CIBA GEIGY AG (CH) | 1989-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | KMO 610/4885CYP17A1 3295/4885CHRM4 636/4885 |
| US-20210171527-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORC, RORB, RORA | KMO 2786/4885CYP17A1 27/4885CHRM4 1394/4885 |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | KMO 2823/4885CYP17A1 1682/4885CHRM4 4808/4885 |
| US-10450314-B2 | Pteridine derivatives as modulators of ROR gamma | RORB, RORC, RORA | KMO 779/4885CYP17A1 36/4885CHRM4 2110/4885 |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | KMO 1106/4885CYP17A1 1253/4885CHRM4 4721/4885 |
| US-11358967-B2 | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma | RORC, RORB, RORA | KMO 990/4885CYP17A1 68/4885CHRM4 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.